Gilead Sciences Inc buy Traumtanz
Start price
04.04.20
/
50%
€74.99
Target price
18.04.20
-
Performance (%)
5.08%
End price
18.04.20
€78.80
Summary
This prediction ended on 18.04.20 with a price of €78.80. The BUY prediction by Traumtanz finished with a performance of 5.08%. Traumtanz has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Gilead Sciences Inc | 0.575% | 0.575% | 5.781% | 24.294% |
iShares Core DAX® | 0.347% | 2.173% | 18.599% | 21.611% |
iShares Nasdaq 100 | 0.715% | 0.138% | 26.542% | 40.349% |
iShares Nikkei 225® | 1.522% | 2.003% | 13.220% | 3.542% |
iShares S&P 500 | 0.631% | 1.633% | 25.009% | 42.942% |
According to Traumtanz what are the pros and cons of Gilead Sciences Inc for the foreseeable future?
Pros
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Strong uniques
Small Risks for its business
Could be very worthwhile Investment >20% year
Cons
Comments by Traumtanz for this prediction
In the thread Gilead Sciences Inc diskutieren
Buy Gilead Sciences Inc
ValueFreak schrieb am 11.04.20:
Die kommenden Wochen dürften spannend sein für Investoren und insbesondere auch für die, die Medizin benötigen
https://www.bloomberg.com/news/articles/2020-04-10/two-thirds-of-severe-covid-19-improved-on-gilead-s-remdesivir
Several large scale clinical trials are underway to evaluate the benefit of remdesivir for Covid-19, the disease caused by the novel coronavirus that has infected more than 1.65 million people worldwide and killed 100,000. One that was conducted in China could report results this month. Another, sponsored by the U.S. National Institutes of Health, has enrolled patients rapidly as the virus spread throughout the U.S. It could also report results in the coming weeks. Gilead itself is sponsoring an additional two trials.
https://www.bloomberg.com/news/articles/2020-04-10/two-thirds-of-severe-covid-19-improved-on-gilead-s-remdesivir
Several large scale clinical trials are underway to evaluate the benefit of remdesivir for Covid-19, the disease caused by the novel coronavirus that has infected more than 1.65 million people worldwide and killed 100,000. One that was conducted in China could report results this month. Another, sponsored by the U.S. National Institutes of Health, has enrolled patients rapidly as the virus spread throughout the U.S. It could also report results in the coming weeks. Gilead itself is sponsoring an additional two trials.
es ist wie es ist und Gilead dümpelt einfach immer weiter wie bisher !
In the thread Trading Gilead Sciences Inc
Einschätzung wurde nach dem Ende von Catch the Monkey automatisch beendet.
Stopped prediction by Traumtanz for Gilead Sciences Inc
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€56.02
06.04.21
06.04.21
€60.00
06.04.22
06.04.22
3.82%
01.07.21
01.07.21
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€48.01
18.12.20
18.12.20
€45.00
-1.78%
23.12.20
23.12.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€51.30
14.11.20
14.11.20
-
14.11.21
14.11.21
-1.75%
23.11.20
23.11.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€50.60
13.11.20
13.11.20
€52.00
1.38%
14.11.20
14.11.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€50.00
09.11.20
09.11.20
€55.00
2.66%
10.11.20
10.11.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€49.75
31.10.20
31.10.20
-
04.11.21
04.11.21
0.53%
09.11.20
09.11.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€54.61
23.10.20
23.10.20
€55.00
31.10.20
31.10.20
-8.91%
31.10.20
31.10.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€51.42
20.10.20
20.10.20
€50.00
22.10.20
22.10.20
-1.26%
22.10.20
22.10.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€55.32
26.08.20
26.08.20
€50.00
08.10.20
08.10.20
-2.68%
08.10.20
08.10.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€55.59
19.08.20
19.08.20
€52.00
24.08.20
24.08.20
0.76%
24.08.20
24.08.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€67.00
20.06.20
20.06.20
€55.00
03.08.20
03.08.20
-10.91%
03.08.20
03.08.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€66.80
20.05.20
20.05.20
€60.00
25.05.20
25.05.20
4.09%
25.05.20
25.05.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€77.45
30.04.20
30.04.20
€85.00
04.05.20
04.05.20
-5.28%
04.05.20
04.05.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€70.00
21.03.20
21.03.20
-
04.04.20
04.04.20
3.16%
04.04.20
04.04.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€76.81
19.03.20
19.03.20
€85.00
19.03.20
19.03.20
-3.91%
19.03.20
19.03.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€64.45
11.03.20
11.03.20
€55.00
11.03.20
11.03.20
0.51%
11.03.20
11.03.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€72.20
07.03.20
07.03.20
-
10.03.20
10.03.20
-13.56%
10.03.20
10.03.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€62.32
28.02.20
28.02.20
€58.00
07.03.20
07.03.20
9.27%
07.03.20
07.03.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€57.14
27.10.19
27.10.19
€50.00
03.02.20
03.02.20
6.00%
03.02.20
03.02.20
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€59.93
13.06.19
13.06.19
€45.10
07.08.19
07.08.19
-3.22%
07.08.19
07.08.19
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€58.18
13.05.19
13.05.19
€45.10
13.06.19
13.06.19
4.48%
13.06.19
13.06.19
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€55.99
25.04.19
25.04.19
€45.10
25.04.19
25.04.19
3.20%
25.04.19
25.04.19
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€77.35
03.02.16
03.02.16
€90.00
09.02.17
09.02.17
-18.07%
09.02.17
09.02.17
Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model